Acute Lymphoblastic Leukaemia Recurrent Recruiting Phase 1 / 2 Trials for Blinatumomab (DB09052)

Also known as: Acute, recurrent Lymphoblastic Leukaemia / Acute, recurrent Lymphoblastic Leukemia / Recurrent Acute lymphoblastic leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphoblastic leukemia recurrent / Relapsed ALL / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03512405Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaTreatment